Leo I Gordon Selected Research

pembrolizumab

6/2023	Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma.
1/2023	Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
11/2021	Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Leo I Gordon Research Topics

Disease

56	Neoplasms (Cancer) 01/2024 - 05/2002
47	Lymphoma (Lymphomas) 12/2023 - 04/2003
44	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2024 - 02/2002
20	Hodgkin Disease (Hodgkin's Disease) 06/2023 - 06/2007
17	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2024 - 06/2004
17	B-Cell Lymphoma (Lymphoma, B Cell) 11/2023 - 07/2003
16	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2023 - 02/2008
13	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018 - 06/2002
8	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2023 - 07/2003
7	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 07/2005
5	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 12/2021 - 07/2008
5	Multiple Myeloma 05/2018 - 02/2002
4	Genetic Translocation (Chromosomal Translocation) 01/2017 - 09/2013
3	Burkitt Lymphoma (Burkitt's Lymphoma) 11/2020 - 07/2012
3	Thrombocytopenia (Thrombopenia) 10/2013 - 06/2002
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 10/2023 - 10/2013
2	Infections 02/2023 - 11/2020
2	Neutropenia 01/2023 - 10/2013
2	Disease Progression 05/2022 - 01/2020
2	COVID-19 04/2022 - 11/2020
2	Cytokine Release Syndrome 01/2021 - 05/2018
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2015
2	Starvation 02/2013 - 07/2003
2	Leukemia 01/2013 - 09/2012
2	Hypoxia (Hypoxemia) 01/2013 - 05/2008
2	Acute Promyelocytic Leukemia 09/2012 - 02/2002
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 09/2007 - 04/2003

Drug/Important Bio-Agent (IBA)

26	Rituximab (Mabthera)FDA Link 12/2023 - 05/2002
20	ibritumomab tiuxetan (Zevalin)FDA Link 10/2009 - 02/2002
12	Proteins (Proteins, Gene)FDA Link 11/2021 - 07/2003
9	YttriumIBA 09/2007 - 02/2002
8	Chimeric Antigen ReceptorsIBA 11/2023 - 05/2018
7	Dacarbazine (DIC)FDA LinkGeneric 06/2023 - 02/2013
7	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2023 - 06/2012
6	Vinblastine (Vinblastine Sulfate)FDA Link 06/2023 - 02/2013
6	Monoclonal AntibodiesIBA 11/2021 - 07/2005
6	HDL LipoproteinsIBA 01/2021 - 02/2013
6	CholesterolIBA 01/2021 - 02/2013
5	Bleomycin (Blenoxane)FDA LinkGeneric 01/2019 - 06/2007
5	Cyclin D1IBA 01/2017 - 08/2011
5	Prednisone (Sone)FDA LinkGeneric 10/2016 - 04/2009
5	Vincristine (Oncovin)FDA LinkGeneric 10/2016 - 04/2009
5	Bortezomib (Velcade)FDA Link 08/2014 - 05/2009
4	venetoclaxIBA 10/2023 - 12/2017
4	Arsenic Trioxide (Trisenox)FDA Link 01/2013 - 02/2002
4	motexafin gadoliniumIBA 04/2010 - 02/2005
4	Yttrium-90IBA 04/2009 - 04/2003
3	Immune Checkpoint InhibitorsIBA 01/2024 - 11/2016
3	ibrutinibIBA 12/2023 - 01/2017
3	Agammaglobulinaemia Tyrosine KinaseIBA 11/2023 - 01/2017
3	Immunoconjugates (Immunoconjugate)IBA 11/2023 - 08/2012
3	pembrolizumabIBA 06/2023 - 11/2021
3	Etoposide (VP 16)FDA LinkGeneric 01/2023 - 04/2013
3	GoldIBA 01/2022 - 02/2013
3	Phosphotransferases (Kinase)IBA 11/2021 - 09/2012
3	high density lipoprotein receptorsIBA 01/2021 - 02/2013
3	Scavenger Receptors (Scavenger Receptor)IBA 01/2019 - 02/2013
3	Brentuximab VedotinIBA 01/2019 - 05/2014
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2016 - 04/2009
3	Histone Deacetylase InhibitorsIBA 03/2016 - 05/2009
3	abexinostatIBA 03/2016 - 05/2009
3	Biomarkers (Surrogate Marker)IBA 01/2016 - 06/2006
3	DNA (Deoxyribonucleic Acid)IBA 05/2013 - 12/2012
3	CaspasesIBA 10/2010 - 05/2009
3	PorphyrinsIBA 10/2009 - 02/2005
3	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2009 - 02/2005
2	AnthracyclinesIBA 01/2024 - 01/2022
2	SteroidsIBA 01/2024 - 01/2020
2	ublituximabIBA 10/2023 - 01/2023
2	umbralisibIBA 10/2023 - 01/2023
2	Lenalidomide (CC 5013)FDA Link 10/2023 - 01/2018
2	TAK-659IBA 02/2023 - 01/2020
2	Lipoproteins (Lipoprotein)IBA 01/2021 - 11/2017
2	GlucocorticoidsIBA 01/2020 - 01/2013
2	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2020 - 01/2013
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020 - 01/2013
2	idelalisibIBA 04/2018 - 12/2017
2	Bevacizumab (Avastin)FDA Link 12/2015 - 06/2006
2	Mechlorethamine (Nitrogen Mustard)FDA Link 06/2015 - 04/2013
2	Nucleic AcidsIBA 01/2015 - 05/2013
2	pidilizumabIBA 09/2014 - 11/2013
2	Formaldehyde (Formol)FDA Link 02/2013 - 10/2012
2	ParaffinIBA 02/2013 - 10/2012
2	CurcuminIBA 08/2011 - 04/2011
2	Glutathione (Reduced Glutathione)IBA 08/2010 - 07/2005

Therapy/Procedure

58	Therapeutics 03/2024 - 06/2002
26	Drug Therapy (Chemotherapy) 01/2024 - 06/2002
16	Radioimmunotherapy 01/2018 - 02/2002
7	Stem Cell Transplantation 01/2022 - 10/2013
5	Immunotherapy 03/2024 - 05/2002
4	Radiotherapy 01/2022 - 02/2013
4	Aftercare (After-Treatment) 05/2009 - 04/2003
3	Hematopoietic Stem Cell Transplantation 08/2023 - 04/2010
2	Salvage Therapy 01/2023 - 04/2010
2	Transplantation 01/2022 - 11/2010
2	Precision Medicine 01/2019 - 01/2013
2	Lymphatic Irradiation 01/2019 - 06/2014
2	Treatment Delay 01/2018 - 10/2013
2	Induction Chemotherapy 10/2016 - 07/2010
2	Combination Drug Therapy (Combination Chemotherapy) 06/2015 - 11/2013